Schisandrin B Exacerbates Acute Pancreatitis by Driving Pathological Pancreatic Secretion
Description
Aim: In this project, we study the treatment effect of Schisandrin B in a Caerulein induced acute pancreatitis mouse model. Methods: Caerulein was administered at hourly intervals for a total of eight injections (100 µg/kg per injection) on two consecutive days. SchB was administered once daily at doses of 30 mg/kg or 60 mg/kg. Mice were euthanized either one hour after the final caerulein injection on day 2 or 16 hours after the final injection on day 3. Blood serum and pancreata were collected for further studies, including H&E (pancreata), IHC (pancreata, CD45), Biochemical study (serum, α-amylase activity), and RNA-Seq (pancreata). Data description: In folder "pancreata_H&E_pathology scoring", include: high power fields (HPFs) images for each mice. The numbering information, scoring raw data, data processing can be found in the excel. In folder" pancreata_IHC_CD45", include: HFPs images for each mice. The numbering information, image-pro-plus setting parameters for macro-detecting positive cells. The detail information (raw data, data processing and summary of CD45 positive ratio ) is presented in the excel. In folder" supplemental tables", include: H&E injury area, α-amylase detection, supplementary_Table1 (RNA-Seq, all significant DEGs list), Supplementary_Table2(RNA-Seq, significantly enriched KEGG pathway list) Conclusion: SchB exacerbates acute pancreatitis, potentially by transcriptionally promoting the overproduction of digestive enzymes and enhancing pancreatic auto-digestion.